The path ahead for the FDA
In a Coalition for Healthcare Communication webinar, former FDA exec Nancy Bradish Myers reflected on the agency’s tumultuous 2020 and charted a path forward for 2021.
FDA
FDA’s Center for Tobacco Products issues $900m Real Cost RFP
The government agency is looking for firms to continue work started in 2014 with several add-ons.
The MM+M Podcast 11.18.2020: Otsuka and WOCIP’s Dr. Charlotte Jones-Burton
Dr. Charlotte Jones-Burton, VP of Otsuka and president and co-founder of WOCIP, weighs in on recent statements concerning Vice-President-elect Kamala Harris’ Black heritage, and offers her take on other news.
Biogen’s touted Alzheimer’s drug receives thumbs-down from FDA advisory panel
The agency will issue its final verdict on approval in March.
The MM+M Podcast 10.14.2020: FDA’s Bakul Patel
In this episode, Bakul Patel speaks about the agency’s new Digital Health Center of Excellence.
FDA cracks down on e-cigarette makers that didn’t submit marketing applications
The agency sent warning letters to vape companies selling e-cigarettes without premarket authorization.
Behind ‘the apology’: Wayne Pines, who counseled FDA Commissioner Hahn to clarify plasma remarks, addresses the controversy
The comms veteran, who found himself at the center of a feud between the commissioner and HHS, also discusses concerns about the agency’s independence.
Five things for pharma marketers to know: Wednesday, September 9, 2020
Pharma companies pledge to only seek approval for safe and effective COVID-19 vaccines; A vaccine before the November election is unlikely, Fauci says; Uber Health head to depart.
Five things for pharma marketers to know: Tuesday, September 1, 2020
FDA may grant emergency use of a vaccine before trials end; Most Americans believe COVID-19 vaccine approval is driven by politics; Aimmune to be acquired by Nestle.
Five things for pharma marketers to know: Tuesday, August 25, 2020
FDA grants emergency use authorization for plasma in treatment of COVID-19; NIH to study another Gilead coronavirus drug candidate; First documented case of reinfection with COVID-19 raises questions.
